- KR₩128bn
- KR₩258bn
- KR₩172bn
- 30
- 48
- 54
- 40
Annual balance sheet for CKD Bio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,533 | 3,535 | 12,724 | 3,700 | 1,164 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 25,342 | 29,907 | 27,471 | 34,108 | 31,259 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 88,382 | 104,342 | 123,464 | 111,769 | 115,212 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 191,189 | 191,153 | 181,509 | 172,509 | 159,161 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 283,463 | 298,540 | 312,591 | 293,785 | 284,492 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 46,114 | 44,311 | 81,591 | 98,618 | 90,681 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 114,715 | 137,049 | 164,792 | 170,761 | 153,483 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 168,748 | 161,491 | 147,799 | 123,024 | 131,009 |
Total Liabilities & Shareholders' Equity | 283,463 | 298,540 | 312,591 | 293,785 | 284,492 |
Total Common Shares Outstanding |